Mylan deal removes uncertainty over launch of Trastuzumab biosimilar: Biocon Chief

Global healthcare company Mylan has inked a settlement pact with Genentech and Roche in relation to patents for cancer drug Herceptin (Trastuzumab).

The settlement gives Mylan global licence to commercialise its Trastuzumab product in various markets around the world.

Trastuzumab is sold under brand name Herceptin. It is an antibody used to treat breast cancer.

In an interview with CNBC-TV18, Kiran Mazumdar Shaw, Biocon Chief, said that this is important news as it removes the uncertainty about Mylan being able to launch biosimilar Trastuzumab.

“Companies have to play the patent dance, which is extremely long and does not give certainty on the launch of a product.” After signing the pact, Mylan can assure its investors regarding the predictability on the launch of Trastuzumab, she added.

Apart from US, Mylan has no patent litigations in Europe with respect to Trastuzumab.

Shaw also assured that the company is firm and committed to USD 200 million revenue in FY19 in terms of its biosimilars.

Biocon and Mylan have one of the longest-standing partnerships in the global biosimilars space and this settlement comes as positive news for both the companies.

To know more, watch video...